Drug intelligence / Profile preview

Methylenedioxyethamphetamine

Development stage
Unknown
Lead developer
Multidisciplinary Association for Psychedelic Studies
Modality
Small Molecules
Administration
Oral, Insufflation, Injection, Rectal
01

Overview

Methylenedioxyethamphetamine, also known as MDEA or "Eve," is an empathogenic psychoactive drug belonging to the substituted amphetamine and methylenedioxyphenethylamine classes. It is often referred to as a "rave" or "designer" drug and is produced in clandestine laboratories for illicit use. MDEA acts as a serotonin, norepinephrine, and dopamine releasing agent and reuptake inhibitor, leading to increased extracellular levels of these monoamines. It can induce dose-related hyperthermia and has been shown to cause neurotoxic effects, particularly in serotonergic neurons, including reduced serotonin content and transporter density. MDEA is an illegal recreational drug in most countries and has no accepted medical uses, carrying risks of severe adverse health effects such as serotonin syndrome, cardiovascular issues, and potentially fatal outcomes from overdose.

Brand names
Eve
02

Targets

SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)VMAT2 (Vesicular monoamine transporter 2)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on Methylenedioxyethamphetamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Methylenedioxyethamphetamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call